Acelyrin Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Cash & Equivalents	218.1	267.11	102.24
Short-Term Investments	503.23	47.51	0
Cash & Cash Equivalents	721.33	314.62	102.24
Cash Growth	129.27%	207.72%	-
Other Current Assets	15.31	1.44	0.06
Total Current Assets	736.64	316.06	102.3
Property, Plant & Equipment	3.37	0	0
Other Long-Term Assets	2.68	3.86	0
Total Long-Term Assets	6.05	3.86	0
Total Assets	742.69	319.92	102.3
Accounts Payable	41.92	5.95	1.13
Other Current Liabilities	43.24	9.95	10.61
Total Current Liabilities	85.16	15.9	11.74
Long-Term Debt	1.19	0	0
Other Long-Term Liabilities	0	10.29	0
Total Long-Term Liabilities	1.19	10.29	0
Total Liabilities	86.35	26.19	11.74
Total Debt	1.19	0	0
Retained Earnings	-488.72	-107.08	-42.31
Comprehensive Income	0.16	-0.09	0
Shareholders' Equity	656.34	-102.86	-42.06
Net Cash / Debt	720.13	314.62	102.24
Net Cash / Debt Growth	128.89%	207.72%	-
Net Cash Per Share	10.25	202.00	148.74
Working Capital	651.48	300.16	90.56
Book Value Per Share	9.34	-66.04	-61.18

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).